Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies-Reference-Cited by-同舟云学术

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Published:2022-02-11 Issue:6 Volume:75 Page:1081-1084
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Timsit Jean Francois¹²,Paul Mical³,Shields Ryan K⁴,Echols Roger⁵,Baba Takamichi⁶,Yamano Yoshinori⁶,Portsmouth Simon⁷

Affiliation:

1. Infection, Antimicrobials, Modelling, Evolution Research Center, Université de Paris (Paris-Diderot) , UMR 1137, Paris , France

2. Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris (AP-HP) , Hôpital Bichat, Paris , France

3. Division of Infectious Diseases, Rambam Health Care Campus, and Technion Israel Institute of Technology Ruth and Bruce Rappaport Faculty of Medicine , Haifa , Israel

4. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA

5. Infectious Disease Drug Development Consulting, LLC , Easton, Connecticut , USA

6. Shionogi & Co, Ltd , Osaka , Japan

7. Shionogi, Inc , Florham Park, New Jersey , USA

Abstract

Abstract In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively).

Funder

Shionogi & Co, Ltd

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac078/45614036/ciac078.pdf

Reference12 articles.

1. Therapeutic options for metallo-β-lactamase-producing Enterobacterales.;Tan;Infect Drug Resist,2021

2. Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline.;Boyd;Antimicrob Agents Chemother,2020

3. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-β-lactamase-producing Enterobacterales during a regional outbreak.;Falcone;Open Forum Infect Dis,2020